Victoria Davis News
-
Cancer medicines that cost more than $100,000 a year aren’t morally justifiable and may keep patients from getting life-saving treatments, a group of more than 100 leukemia doctors said.
-
Pfizer Inc.’s Fablyn, the bone drug that failed to win U.S. approval amid safety questions, reduced the risk of breast cancer and fractures in postmenopausal women with osteoporosis, a company-sponsored study found.
-
Pfizer Inc.’s experimental rheumatoid arthritis pill won U.S. regulatory approval and will compete directly with Abbott Laboratories’ top-selling injection Humira.
-
Pfizer Inc.’s experimental rheumatoid arthritis pill tofacitinib eased symptoms of patients with ulcerative colitis, an inflammatory bowel disease that affects 750,000 Americans, a company-sponsored study showed.
-
Pfizer Inc . shares fell the most since August after a study summary published online showed four deaths among patients taking the company’s experimental rheumatoid arthritis pill.
-
Paul G. Allen, a Microsoft Corp. co- founder who was once the second-richest American, accused 11 companies including Google Inc. and Apple Inc. of infringing patents he holds for online-shopping technology.
-
Pfizer Inc. ’s menopause drug Prempro didn’t cause two women’s cancers, and the drugmaker doesn’t have to pay damages over those illnesses, a jury decided.
-
Pfizer Inc.’s experimental pill for rheumatoid arthritis was as effective as Humira from Abbott Laboratories and showed no new side effects in study results the company plans to submit for U.S. approval this year.
-
Japan’s health ministry suspended the use of pediatric vaccines made by Pfizer Inc. and Sanofi- Aventis SA after reports of four deaths following immunizations.
|
|
Most Popular on Bloomberg
|
| |
Rate this Page